The evidence on peptides — delivered weekly. Subscribe free →

MOTS-c

unknown risk

Also: Mitochondrial Open Reading Frame of the 12S rRNA-c

Preliminary Research Only

MOTS-c is a mitochondria-derived peptide (MDP) encoded within the 12S rRNA gene. It acts as an exercise mimetic, activating AMPK and improving metabolic flexibility, with emerging evidence for anti-aging properties.

Molecular Weight
1398.6 g/mol
Formula
C59H95N15O25S2
Common Dosing
Not established; animal studies use 0.5-5 mg/kg
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Metabolic Enhancement

Preliminary 12 studies

Activates AMPK, improves insulin sensitivity, and mimics exercise adaptations in animal models.

Exercise Mimetic

Preliminary 8 studies

Mice receiving MOTS-c show improved exercise performance and metabolic adaptation without training.

Anti-aging

Preliminary 5 studies

Preliminary data links MOTS-c decline to aging-related metabolic dysfunction.

Mechanism of Action

MOTS-c enters the cell nucleus and regulates metabolic gene expression, activating AMPK (the cellular energy sensor) and the folate cycle/AICAR pathway. This drives mitochondrial biogenesis, improved glucose metabolism, and anti-inflammatory gene expression changes.

Key Clinical Studies

Lee C et al. (2015)

animal · Mice

PubMed →

MOTS-c activates AMPK, reverses diet-induced obesity

Reynolds JC et al. (2021)

animal · Aged mice

MOTS-c improves physical performance in old mice

Overview

MOTS-c is one of the most intriguing recently discovered mitochondria-derived peptides. Its classification as an “exercise mimetic” — producing metabolic adaptations similar to physical exercise without exercise itself — has attracted significant attention from both anti-aging researchers and sports medicine communities.

AMPK Connection

The central mechanism — AMPK activation — connects MOTS-c to one of the most well-validated metabolic pathways in biology. Metformin (the most prescribed diabetes drug) works partly through AMPK. Caloric restriction extends lifespan partly through AMPK. MOTS-c activating this pathway through mitochondrial signaling represents a novel upstream entry point.

Human Data Gap

Unlike humanin (which has some human data), MOTS-c is entirely in preclinical stages. No completed human trials exist. The mechanism is compelling and the animal data is promising, but translation to human benefit at safe doses remains undemonstrated.

Nuclear Translocation

A fascinating feature of MOTS-c is its ability to translocate to the cell nucleus and directly regulate gene expression — a property not expected from a mitochondrially derived peptide. This nuclear activity may account for the breadth of its metabolic effects and represents an active area of mechanistic investigation.

Regulatory Status

Research Only

Not FDA-approved; preclinical research stage; no clinical trials completed

Safety Profile

Side Effects

  • No significant adverse effects in animal studies

Contraindications

  • Pregnancy (insufficient data)

Drug Interactions

  • Metformin (AMPK overlap, potentially synergistic)

Primary Uses

Mitochondrial healthMetabolic healthExercise mimeticAnti-aging

Related Peptides

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe MOTS-c?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.